Welcome to our dedicated page for Surgalign Holdings news (Ticker: SRGA), a resource for investors and traders seeking the latest updates and insights on Surgalign Holdings stock.
Surgalign Holdings, Inc. (SRGA) is a prominent medical technology company that specializes in the design, development, manufacture, and distribution of biologic, metal, and synthetic implants worldwide. Established in 1997 and headquartered in Deerfield, Illinois, Surgalign Holdings has carved out a significant niche in the fields of orthopedics, spine, sports medicine, plastic surgery, trauma, and other surgical procedures.
The company offers a range of innovative products aimed at improving surgical outcomes and promoting natural healing. Among its key offerings is the Coflex Interlaminar Stabilization Device, which is designed to treat moderate to severe lumbar spinal stenosis in conjunction with decompression. Additionally, the Simmetry Sacroiliac Joint Fusion System is known to decrease opioid use, pain, and disability. Another notable product is the Fortilink IBF System with TETRAfuse 3D technology, enhancing the integration and fusion of spinal implants.
Surgalign’s state-of-the-art implants are utilized by healthcare providers, hospitals, and various healthcare facilities through a robust distribution network. The company leverages its direct distribution force, OEM relationships, and an extensive network of independent distributors to reach its clients effectively. Surgalign's commitment to quality and innovation has positioned it as a leader in medical technology, dedicated to enhancing patient outcomes and advancing the field of surgical implants.
For more information, the latest updates, and media inquiries, please contact Glenn Wiener at gwiener@gwcco.com or +1 917 887 8434.
Surgalign Holdings (NASDAQ: SRGA) announced the granting of restricted stock unit awards to 10 new employees as an inducement for their acceptance of employment. The total awards amount to 91,925 shares and were granted under the 2021 Inducement Plan. Vesting occurs in stages, with one-third vesting after one year, and the remainder vesting quarterly over two years. The awards were approved by an independent Compensation Committee. This move aligns with Surgalign's strategy to enhance its digital surgery platform and elevate surgical care standards.
Surgalign Spine Technologies (NASDAQ: SRGA) announced it will release its second quarter 2021 financial results before trading opens on August 6, 2021. An audio conference call will follow at 9:00 a.m. ET, accessible via phone or webcast. The company is focused on advancing digital surgery solutions globally, operating in over 50 countries. Surgalign aims to provide superior clinical and economic outcomes for surgeons and patients alike. For more details, visit surgalign.com.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has announced the grant of restricted stock unit awards totaling up to 74,460 shares to nine employees as an inducement for accepting employment. The awards, approved by the independent Compensation Committee, are part of the company’s 2021 Inducement Plan and vest over three years. Surgalign focuses on advancing digital surgery and improving surgical outcomes. The company is headquartered in Deerfield, IL, and operates globally, enhancing care through innovative technologies.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced its participation in the Sidoti Virtual Investor Conference on June 23, 2021, at 2:30 p.m. ET. The company's management will present via webcast, accessible through their investor relations page. Surgalign, a medical technology firm based in Deerfield, IL, focuses on enhancing surgical standards through digital surgery innovation. Their products reach over 50 countries, aiming to provide superior clinical outcomes. A replay of the presentation will be available online post-event.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced the closing of a registered direct offering, issuing 28,985,508 shares of common stock and warrants, generating approximately $50 million in gross proceeds. The shares and warrants were priced at $1.725 each, under Nasdaq rules. The funds will be used for working capital and to advance its digital surgical guidance system. The offering was facilitated by H.C. Wainwright & Co. and was conducted under an effective shelf registration statement.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has executed a securities purchase agreement with institutional investors to offer 28,985,508 shares of common stock and warrants at $1.725 per share. This registered direct offering aims to raise approximately $50 million before expenses. The proceeds will support working capital and the advancement of Surgalign's digital surgical guidance system. The offering is expected to close on June 14, 2021, subject to customary conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for this transaction.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has entered a strategic collaboration with Inteneural Networks Inc. to evaluate the integration of AI-based applications for central nervous system imaging within its digital surgery portfolio. This partnership aims to enhance research and development efficiency and expand Surgalign's market reach. Inteneural's technology, which autonomously segments neural structures, has potential applications in cranial and neurosurgery.
The collaboration is based on positive feedback from spine surgeons who also specialize in neurosurgery.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced the granting of equity awards to six non-executive employees as an employment inducement on June 1, 2021. These awards, totaling up to 179,667 shares, include 116,751 stock options priced at $1.80 and 62,916 restricted stock units. Vesting for stock options occurs over four years, while restricted stock units vest over three years. This decision was approved by the independent Compensation Committee and aligns with Nasdaq regulations, aiming to attract talent to promote digital surgery solutions.
Surgalign Holdings (NASDAQ: SRGA), a global medical technology company, will participate in the Craig-Hallum Institutional Investor Conference on June 2, 2021. The company is focused on advancing digital surgery to improve surgical outcomes and is expanding its product offerings in over 50 countries. Headquartered in Deerfield, IL, Surgalign is committed to creating solutions that provide superior clinical and economic results for surgeons. For more information, visit www.surgalign.com.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has announced the granting of equity awards to five employees as an inducement for joining the company. This includes stock options for 202,971 shares at an exercise price of $1.73, and restricted stock units for 107,659 shares, with vesting schedules depending on continued employment. The awards, approved by the independent Compensation Committee, amount to a total of 467,404 shares under the Surgalign Holdings 2021 Inducement Plan, aimed at enhancing employee retention and alignment with company goals.
FAQ
What does Surgalign Holdings, Inc. specialize in?
Where is Surgalign Holdings, Inc. headquartered?
What are some key products offered by Surgalign Holdings, Inc.?
How does Surgalign distribute its products?
In which medical fields are Surgalign’s implants used?
When was Surgalign Holdings, Inc. founded?
What is the purpose of the Coflex Interlaminar Stabilization Device?
How does the Simmetry Sacroiliac Joint Fusion System benefit patients?
What technology does the Fortilink IBF System utilize?
Who should be contacted for media inquiries about Surgalign Holdings, Inc.?
